| アブストラクト | The prodrug fosphenytoin (FOS) was recently introduced as an alternative to phenytoin (PTN) and has since become a first line therapy for status epilepticus. Unlike PTN, FOS generally has been considered to be safe from cardiac toxicity. To better characterize cardiac toxicity associated with FOS administration, we performed a review of the Food and Drug Administration's Adverse Event Reporting System databank for reports of possible FOS toxicity from 1997-2002. There were 29 applicable reports of adverse cardiac events likely related to FOS infusion, including 10 cardiac deaths. Among survivors, there were four cases of high-grade atrioventricular block, and five cases of transient sinus arrest. Our data suggest that FOS may produce more cardiac toxicity than previously thought. Clinicians should consider administering intravenous FOS in a monitored setting for selected high-risk patients. |
|---|
| ジャーナル名 | The Journal of emergency medicine |
|---|
| Pubmed追加日 | 2006/01/26 |
|---|
| 投稿者 | Adams, Bruce D; Buckley, Neil H; Kim, James Y; Tipps, Lia B |
|---|
| 組織名 | Department of Emergency Medicine, Brooke Army Medical Center, San Antonio, Texas,;USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/16434340/ |
|---|
